Related Experiment Video

Updated: Jun 13, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Benchmarking spleen tyrosine kinase (Syk) expression in T- and NK-cell neoplasms: Implications for therapeutic

Jing-Ping Zhang1, Qi Gao1, Achim A Jungbluth1

  • 1Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

British Journal of Haematology
|May 14, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
SykT‐cell lymphomaflow cytometryimmunohistochemistrynew drugs for lymphoma

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.8K

Related Experiment Videos

Last Updated: Jun 13, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Comprehensive Genomic Characterization of Primary Dermal Melanoma: Delineating it from Metastatic Melanoma with Unknown Primary.

Human pathology·2026

Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.

Blood cancer discovery·2026

Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric study.

medRxiv : the preprint server for health sciences·2026

SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities.

Cancer discovery·2026

Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smears.

Communications medicine·2026

Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary.

Gynecologic oncology reports·2026

Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.

British journal of haematology·2026

Warm autoimmune haemolytic anaemia in Taiwan: A population-based study of epidemiology, treatment patterns, survival and healthcare utilisation (2017-2022).

British journal of haematology·2026

Clinical outcome and infectious complications in genetic and suspected genetic neutropenia: A report from the Canadian Inherited Marrow Failure Registry.

British journal of haematology·2026

SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.

British journal of haematology·2026

CALR-mutated myeloproliferative neoplasms: Refining molecular risk beyond the driver.

British journal of haematology·2026

RESOLVE to do better.

British journal of haematology·2026

Integrating a Tumor Size-Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody-Drug Conjugates in Non-Small Cell Lung Cancer.

CPT: pharmacometrics & systems pharmacology·2026

The Future of all-Comers Trials in the Era of Precision Oncology.

Clinical pharmacology and therapeutics·2026

Tumor Treating Fields Enhance Temozolomide-Associated Growth Suppression in Glioblastoma Cells and Patient-Derived Organoids Through Cell-Cycle Blockade, Apoptosis, and SMAD-Associated Signaling.

CNS neuroscience & therapeutics·2026

MyoD and Myogenin regulatory cascade is targeted by tumor signals to repress myogenesis in cancer cachexia.

The Biochemical journal·2026

Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus).

Journal of Alzheimer's disease : JAD·2026

Conferone: Sources, Anticancer Mechanisms, and Potential in Overcoming Chemoresistance - A Comprehensive Review.

Current pharmaceutical design·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us